|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.
With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies.
Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focuses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
"Genome Editing of Immune Cells" - New Lonza Virtual Event
Basel, Switzerland, 06 September 2022 – On September 20, 2022,
Lonza will host a free virtual workshop on using genome editing
technologies for cell and gene therapies and drug discovery. The 3-hour
workshop brings together renowned genome editing experts from across
industry and academia and comprises four interactive speaker sessions
and a concluding panel discussion. The event is a chance for researchers
to engage directly with leading voices in the field, keep up to date
with the latest CRISPR research and application, and discover tips and
tricks for optimized CRISPR editing and screening.
More info >> |
|
 |
White Papers |
 |
|
|
